|Mr. Julian T. Ross M.B.A.||Founder, Chairman, CEO, Pres, CFO, Principal Accounting Officer and Sec.||250k||N/A||50|
|Mr. Clark E. Hood||VP of Worldwide Resuscitation Sales||200k||N/A||54|
|Ms. Lisa Griffin||Director of Safety Education||N/A||N/A||N/A|
|Ms. Kathryn Jayne||Director of Regulatory Affairs & Quality Assurance||N/A||N/A||N/A|
OxySure Therapeutics, Inc. designs, manufactures, and distributes specialty respiratory and emergency medical solutions in the United States and internationally. It offers OxySure Model 615, a portable emergency oxygen system. The company also provides complimentary products and solutions, including display wall boxes, oxygen wall signage, resuscitation bags, pulse oximeters, and automated external defibrillators, as well as thermal bags and replacement cartridges for its OxySure Model 615. Its products enhance the access to emergency oxygen that affects the survival, recovery, and safety of individuals in various areas of need. The company primarily sells its products to institutional customers through distributors, sub-distributors, and sales agents. The company was formerly known as OxySure Systems, Inc. and changed its name to OxySure Therapeutics, Inc. in November 2015. OxySure Therapeutics, Inc. was founded in 2004 and is headquartered in Frisco, Texas. On December 5, 2016, Oxysure Therapeutics, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Eastern District of Texas.
OxySure Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.